肺癌
报销
医学
基因检测
多路复用
精密医学
肿瘤科
癌症
生物信息学
内科学
计算生物学
病理
医疗保健
生物
经济增长
经济
作者
Yasushi Yatabe,Kuniko Sunami,Kōichi Goto,Kazuto Nishio,Naoko Aragane,Sadakatsu Ikeda,Akira Inoue,Ichiro Kinoshita,Hideharu Kimura,Tomohiro Sakamoto,Miyako Satouchi,Junichi Shimizu,Koji Tsuta,Shinichi Toyooka,Kazumi Nishino,Yutaka Hatanaka,Shingo Matsumoto,Masashi Mikubo,Tomoyuki Yokose,Hirotoshi Dosaka‐Akita
摘要
The year 2019 was considered to be the first year of cancer genome medicine in Japan, with three gene‐panel tests using next‐generation sequencing (NGS) techniques being introduced into clinical practice. Among the three tests, the Oncomine CDx Target test was approved under the category of regular molecular testing for lung cancer, which meant that this test could be used to select patients for molecularly targeted drugs. Conversely, the other two tests, NCC OncoPanel and FoundationOne CDx, were assigned to be used under the National Cancer Genome Medicine Network, and implementation was restricted to patients for whom standard treatment was completed or expected to be completed. These NGS tests can detect a series of genetic alterations in individual tumors, which further promotes the development of therapeutic agents and elucidates molecular pathways. The NGS tests require appropriate tissue size and tumor cell content, which can be accessed only by pathologists. In this report, we review the current reimbursement schema in our national healthcare policy and the requirements of the specimens for NGS testing based on the recently published ‘Guidance of Gene‐panel Testing Using Next‐Generation Sequencers for Lung Cancer’, by the Japanese Society of Lung Cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI